Skip to main content
PMC home page
Netherlands Heart Journal logoLink to Netherlands Heart Journal
. 2005 Feb;13(2):47–56.

Risk factors for drug-induced long-QT syndrome

ADC Paulussen, J Aerssens
PMCID: PMC2497238  PMID: 25696450

Abstract

Congenital long-QT syndrome (cLQTS) is a ventricular arrhythmia that is characterised by a prolonged QT interval on the surface electro-cardiogram (ECG). Clinical symptoms include sudden loss of consciousness (syncopes), seizures, cardiac arrest and sudden death. The prevalence of this inherited disease is approximately one in 10,000 in Caucasians. Over the last decade, more than 200 different diseases causing mutations have been identified in five genes that encode ion channels involved in the delicate balance of inward and outward K/Ca currents during the cardiac action potential. A prolonged QT interval accompanied by very similar clinical symptoms as in cLQTS can also occur in otherwise healthy individuals after the intake of specific drug(s). This phenomenon is known as 'acquired' or 'drug-induced' long-QT syndrome. Because the clinical symptoms of the two forms are very similar, the question arises whether a common underlying genetic basis also exists. Several studies indicate that only a minority (approximately 10%) of the drug-induced LQTS cases can be explained by a mutation or polymorphism in one of the known LQTS genes. Even though the disease can often at least partially be explained by environmental factors, mutations or polymorphisms in other genes are also expected to be involved, including genes encoding drug-metabolising enzymes, adrenergic receptors, hormone-related genes and mitochondrial genes. This article reviews the current knowledge on risk factors for drug-induced LQTS, with a special emphasis on the role of genetic determinants.

Keywords: long-QT syndrome, drug-induced, arrhythmia, genetics

Full text

PDF
47

Images in this article

49Figure 1A
on p.49
52Figure 2
on p.52
53Figure 3
on p.53

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abbott G. W., Sesti F., Splawski I., Buck M. E., Lehmann M. H., Timothy K. W., Keating M. T., Goldstein S. A. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell. 1999 Apr 16;97(2):175–187. doi: 10.1016/s0092-8674(00)80728-x. [DOI] [PubMed] [Google Scholar]
  2. Ackerman Michael J., Tester David J., Jones Gregg S., Will Melissa L., Burrow Christopher R., Curran Mark E. Ethnic differences in cardiac potassium channel variants: implications for genetic susceptibility to sudden cardiac death and genetic testing for congenital long QT syndrome. Mayo Clin Proc. 2003 Dec;78(12):1479–1487. doi: 10.4065/78.12.1479. [DOI] [PubMed] [Google Scholar]
  3. Atar Shaul, Freedberg Nahum A., Antonelli Dante, Rosenfeld Tiberio. Torsades de pointes and QT prolongation due to a combination of loratadine and amiodarone. Pacing Clin Electrophysiol. 2003 Mar;26(3):785–786. doi: 10.1046/j.1460-9592.2003.00137.x. [DOI] [PubMed] [Google Scholar]
  4. Bezzina Connie R., Verkerk Arie O., Busjahn Andreas, Jeron Andreas, Erdmann Jeanette, Koopmann Tamara T., Bhuiyan Zahurul A., Wilders Ronald, Mannens Marcel M. A. M., Tan Hanno L. A common polymorphism in KCNH2 (HERG) hastens cardiac repolarization. Cardiovasc Res. 2003 Jul 1;59(1):27–36. doi: 10.1016/s0008-6363(03)00342-0. [DOI] [PubMed] [Google Scholar]
  5. Bran S., Murray W. A., Hirsch I. B., Palmer J. P. Long QT syndrome during high-dose cisapride. Arch Intern Med. 1995 Apr 10;155(7):765–768. [PubMed] [Google Scholar]
  6. Chevalier P., Rodriguez C., Bontemps L., Miquel M., Kirkorian G., Rousson R., Potet F., Schott J. J., Baró I., Touboul P. Non-invasive testing of acquired long QT syndrome: evidence for multiple arrhythmogenic substrates. Cardiovasc Res. 2001 May;50(2):386–398. doi: 10.1016/s0008-6363(01)00263-2. [DOI] [PubMed] [Google Scholar]
  7. Cholerton S., Daly A. K., Idle J. R. The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol Sci. 1992 Dec;13(12):434–439. doi: 10.1016/0165-6147(92)90140-2. [DOI] [PubMed] [Google Scholar]
  8. Choudhury L., Grais I. M., Passman R. S. Torsades de pointes due to drug interaction between disopyramide and clarithromycin. Heart Dis. 1999 Sep-Oct;1(4):206–207. [PubMed] [Google Scholar]
  9. Curran M. E., Splawski I., Timothy K. W., Vincent G. M., Green E. D., Keating M. T. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell. 1995 Mar 10;80(5):795–803. doi: 10.1016/0092-8674(95)90358-5. [DOI] [PubMed] [Google Scholar]
  10. Donger C., Denjoy I., Berthet M., Neyroud N., Cruaud C., Bennaceur M., Chivoret G., Schwartz K., Coumel P., Guicheney P. KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome. Circulation. 1997 Nov 4;96(9):2778–2781. doi: 10.1161/01.cir.96.9.2778. [DOI] [PubMed] [Google Scholar]
  11. Drici M. D., Burklow T. R., Haridasse V., Glazer R. I., Woosley R. L. Sex hormones prolong the QT interval and downregulate potassium channel expression in the rabbit heart. Circulation. 1996 Sep 15;94(6):1471–1474. doi: 10.1161/01.cir.94.6.1471. [DOI] [PubMed] [Google Scholar]
  12. Drici M. D., Knollmann B. C., Wang W. X., Woosley R. L. Cardiac actions of erythromycin: influence of female sex. JAMA. 1998 Nov 25;280(20):1774–1776. doi: 10.1001/jama.280.20.1774. [DOI] [PubMed] [Google Scholar]
  13. Drolet B., Vincent F., Rail J., Chahine M., Deschênes D., Nadeau S., Khalifa M., Hamelin B. A., Turgeon J. Thioridazine lengthens repolarization of cardiac ventricular myocytes by blocking the delayed rectifier potassium current. J Pharmacol Exp Ther. 1999 Mar;288(3):1261–1268. [PubMed] [Google Scholar]
  14. Evans W. E., Relling M. V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 1999 Oct 15;286(5439):487–491. doi: 10.1126/science.286.5439.487. [DOI] [PubMed] [Google Scholar]
  15. Flockhart D. A., Drici M. D., Kerbusch T., Soukhova N., Richard E., Pearle P. L., Mahal S. K., Babb V. J. Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome. J Clin Psychopharmacol. 2000 Jun;20(3):317–324. doi: 10.1097/00004714-200006000-00005. [DOI] [PubMed] [Google Scholar]
  16. Gibbs M. A., Thummel K. E., Shen D. D., Kunze K. L. Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression. Drug Metab Dispos. 1999 Feb;27(2):180–187. [PubMed] [Google Scholar]
  17. Gray V. S. Syncopal episodes associated with cisapride and concurrent drugs. Ann Pharmacother. 1998 Jun;32(6):648–651. doi: 10.1345/aph.17288. [DOI] [PubMed] [Google Scholar]
  18. Hayashi Y., Ikeda U., Hashimoto T., Watanabe T., Mitsuhashi T., Shimada K. Torsades de pointes ventricular tachycardia induced by clarithromycin and disopyramide in the presence of hypokalemia. Pacing Clin Electrophysiol. 1999 Apr;22(4 Pt 1):672–674. doi: 10.1111/j.1540-8159.1999.tb00512.x. [DOI] [PubMed] [Google Scholar]
  19. Hii J. T., Wyse D. G., Gillis A. M., Cohen J. M., Mitchell L. B. Propafenone-induced torsade de pointes: cross-reactivity with quinidine. Pacing Clin Electrophysiol. 1991 Nov;14(11 Pt 1):1568–1570. doi: 10.1111/j.1540-8159.1991.tb02729.x. [DOI] [PubMed] [Google Scholar]
  20. Hsieh M. H., Chen S. A., Chiang C. E., Tai C. T., Lee S. H., Wen Z. C., Chang M. S. Drug-induced torsades de pointes in one patient with congenital long QT syndrome. Int J Cardiol. 1996 Apr 19;54(1):85–88. doi: 10.1016/0167-5273(96)02582-x. [DOI] [PubMed] [Google Scholar]
  21. Ikeda S., Oka H., Matunaga K., Kubo S., Asai S., Miyahara Y., Osaka A., Kohno S. Astemizole-induced torsades de pointes in a patient with vasospastic angina. Jpn Circ J. 1998 Mar;62(3):225–227. doi: 10.1253/jcj.62.225. [DOI] [PubMed] [Google Scholar]
  22. Jenkins I. R., Gibson J. Cisapride, erythromycin and arrhythmia. Anaesth Intensive Care. 1996 Dec;24(6):728–728. [PubMed] [Google Scholar]
  23. Karch M., Schmitt C., Plewan A., Schmidt G., Schömig A. Torsade-de-pointes-Tachykardie unter Einnahme von Chinidin und Verapamil bei Vorhofflimmern. Herz. 1997 Feb;22(1):51–56. doi: 10.1007/BF03044570. [DOI] [PubMed] [Google Scholar]
  24. Keating M., Atkinson D., Dunn C., Timothy K., Vincent G. M., Leppert M. Linkage of a cardiac arrhythmia, the long QT syndrome, and the Harvey ras-1 gene. Science. 1991 May 3;252(5006):704–706. doi: 10.1126/science.1673802. [DOI] [PubMed] [Google Scholar]
  25. Koh K. K., Rim M. S., Yoon J., Kim S. S. Torsade de pointes induced by terfenadine in a patient with long QT syndrome. J Electrocardiol. 1994 Oct;27(4):343–346. doi: 10.1016/s0022-0736(05)80274-2. [DOI] [PubMed] [Google Scholar]
  26. Kowey P. R., VanderLugt J. T., Luderer J. R. Safety and risk/benefit analysis of ibutilide for acute conversion of atrial fibrillation/flutter. Am J Cardiol. 1996 Oct 17;78(8A):46–52. doi: 10.1016/s0002-9149(96)00566-8. [DOI] [PubMed] [Google Scholar]
  27. Kuehl P., Zhang J., Lin Y., Lamba J., Assem M., Schuetz J., Watkins P. B., Daly A., Wrighton S. A., Hall S. D. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001 Apr;27(4):383–391. doi: 10.1038/86882. [DOI] [PubMed] [Google Scholar]
  28. Kyrmizakis Dionysios E., Chimona Theognosia S., Kanoupakis Emmanuel M., Papadakis Chariton E., Velegrakis George A., Helidonis Emmanuel S. QT prolongation and torsades de pointes associated with concurrent use of cisapride and erythromycin. Am J Otolaryngol. 2002 Sep-Oct;23(5):303–307. doi: 10.1053/ajot.2002.124543. [DOI] [PubMed] [Google Scholar]
  29. Lehmann M. H., Hardy S., Archibald D., quart B., MacNeil D. J. Sex difference in risk of torsade de pointes with d,l-sotalol. Circulation. 1996 Nov 15;94(10):2535–2541. doi: 10.1161/01.cir.94.10.2535. [DOI] [PubMed] [Google Scholar]
  30. Lin J. C., Quasny H. A. QT prolongation and development of torsades de pointes with the concomitant administration of oral erythromycin base and quinidine. Pharmacotherapy. 1997 May-Jun;17(3):626–630. [PubMed] [Google Scholar]
  31. Locati E. H., Zareba W., Moss A. J., Schwartz P. J., Vincent G. M., Lehmann M. H., Towbin J. A., Priori S. G., Napolitano C., Robinson J. L. Age- and sex-related differences in clinical manifestations in patients with congenital long-QT syndrome: findings from the International LQTS Registry. Circulation. 1998 Jun 9;97(22):2237–2244. doi: 10.1161/01.cir.97.22.2237. [DOI] [PubMed] [Google Scholar]
  32. Ma Margaret K., Woo Michael H., McLeod Howard L. Genetic basis of drug metabolism. Am J Health Syst Pharm. 2002 Nov 1;59(21):2061–2069. doi: 10.1093/ajhp/59.21.2061. [DOI] [PubMed] [Google Scholar]
  33. Makita Naomasa, Horie Minoru, Nakamura Takeshi, Ai Tomohiko, Sasaki Koji, Yokoi Hisataka, Sakurai Masayuki, Sakuma Ichiro, Otani Hideo, Sawa Hirofumi. Drug-induced long-QT syndrome associated with a subclinical SCN5A mutation. Circulation. 2002 Sep 3;106(10):1269–1274. doi: 10.1161/01.cir.0000027139.42087.b6. [DOI] [PubMed] [Google Scholar]
  34. Marinella M. A., Burdette S. D. Visual diagnosis in emergency medicine. Hypokalemia-induced QT interval prolongation. J Emerg Med. 2000 Nov;19(4):375–376. doi: 10.1016/s0736-4679(00)00265-1. [DOI] [PubMed] [Google Scholar]
  35. Matsuoka R., Furutani M., Hayashi J., Isobe K., Akimoto K., Shibata T., Imamura S., Tatsuguchi M., Furutani Y., Takao A. A mitochondrial DNA mutation cosegregates with the pathophysiological U wave. Biochem Biophys Res Commun. 1999 Apr 2;257(1):228–233. doi: 10.1006/bbrc.1999.0443. [DOI] [PubMed] [Google Scholar]
  36. Michalets E. L., Smith L. K., Van Tassel E. D. Torsade de pointes resulting from the addition of droperidol to an existing cytochrome P450 drug interaction. Ann Pharmacother. 1998 Jul-Aug;32(7-8):761–765. doi: 10.1345/aph.17351. [DOI] [PubMed] [Google Scholar]
  37. Monahan B. P., Ferguson C. L., Killeavy E. S., Lloyd B. K., Troy J., Cantilena L. R., Jr Torsades de pointes occurring in association with terfenadine use. JAMA. 1990 Dec 5;264(21):2788–2790. [PubMed] [Google Scholar]
  38. Moss A. J., Schwartz P. J. Delayed repolarization (QT or QTU prolongation) and malignant ventricular arrhythmias. Mod Concepts Cardiovasc Dis. 1982 Mar;51(3):85–90. [PubMed] [Google Scholar]
  39. Napolitano C., Schwartz P. J., Brown A. M., Ronchetti E., Bianchi L., Pinnavaia A., Acquaro G., Priori S. G. Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. J Cardiovasc Electrophysiol. 2000 Jun;11(6):691–696. doi: 10.1111/j.1540-8167.2000.tb00033.x. [DOI] [PubMed] [Google Scholar]
  40. Nosworthy Adam. Images in clinical medicine. Hypokalemia. N Engl J Med. 2003 Nov 27;349(22):2116–2116. doi: 10.1056/NEJMicm990705. [DOI] [PubMed] [Google Scholar]
  41. Ohki R., Takahashi M., Mizuno O., Fujikawa H., Mitsuhashi T., Katsuki T., Ikeda U., Shimada K. Torsades de pointes ventricular tachycardia induced by mosapride and flecainide in the presence of hypokalemia. Pacing Clin Electrophysiol. 2001 Jan;24(1):119–121. doi: 10.1046/j.1460-9592.2001.00119.x. [DOI] [PubMed] [Google Scholar]
  42. Paulussen Aimée D. C., Gilissen Ronaldus A. H. J., Armstrong Martin, Doevendans Pieter A., Verhasselt Peter, Smeets Hubert J. M., Schulze-Bahr Eric, Haverkamp Wilhelm, Breithardt Günter, Cohen Nadine. Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. J Mol Med (Berl) 2004 Feb 4;82(3):182–188. doi: 10.1007/s00109-003-0522-z. [DOI] [PubMed] [Google Scholar]
  43. Pettignano R., Chambliss C. R., Darsey E., Heard M., Clark R. Cisapride-induced dysrhythmia in a pediatric patient receiving extracorporeal life support. Crit Care Med. 1996 Jul;24(7):1268–1271. doi: 10.1097/00003246-199607000-00035. [DOI] [PubMed] [Google Scholar]
  44. Piquette R. K. Torsade de pointes induced by cisapride/clarithromycin interaction. Ann Pharmacother. 1999 Jan;33(1):22–26. doi: 10.1345/aph.18107. [DOI] [PubMed] [Google Scholar]
  45. Pohjola-Sintonen S., Viitasalo M., Toivonen L., Neuvonen P. Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia. Eur J Clin Pharmacol. 1993;45(2):191–193. doi: 10.1007/BF00315505. [DOI] [PubMed] [Google Scholar]
  46. Priori S. G., Napolitano C., Schwartz P. J. Low penetrance in the long-QT syndrome: clinical impact. Circulation. 1999 Feb 2;99(4):529–533. doi: 10.1161/01.cir.99.4.529. [DOI] [PubMed] [Google Scholar]
  47. Rampe D., Roy M. L., Dennis A., Brown A. M. A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG. FEBS Lett. 1997 Nov 3;417(1):28–32. doi: 10.1016/s0014-5793(97)01249-0. [DOI] [PubMed] [Google Scholar]
  48. Rautaharju P. M., Zhou S. H., Wong S., Calhoun H. P., Berenson G. S., Prineas R., Davignon A. Sex differences in the evolution of the electrocardiographic QT interval with age. Can J Cardiol. 1992 Sep;8(7):690–695. [PubMed] [Google Scholar]
  49. Richards John R., Schneir Aaron B. Droperidol in the emergency department: is it safe? J Emerg Med. 2003 May;24(4):441–447. doi: 10.1016/s0736-4679(03)00044-1. [DOI] [PubMed] [Google Scholar]
  50. Romkes J. H., Froger C. L., Wever E. F., Westerhof P. W. Wegrakingen tijdens simultaan gebruik van terfenadine en itraconazol. Ned Tijdschr Geneeskd. 1997 May 10;141(19):950–953. [PubMed] [Google Scholar]
  51. Sanguinetti M. C., Curran M. E., Zou A., Shen J., Spector P. S., Atkinson D. L., Keating M. T. Coassembly of K(V)LQT1 and minK (IsK) proteins to form cardiac I(Ks) potassium channel. Nature. 1996 Nov 7;384(6604):80–83. doi: 10.1038/384080a0. [DOI] [PubMed] [Google Scholar]
  52. Sanguinetti M. C., Jurkiewicz N. K. Role of external Ca2+ and K+ in gating of cardiac delayed rectifier K+ currents. Pflugers Arch. 1992 Feb;420(2):180–186. doi: 10.1007/BF00374988. [DOI] [PubMed] [Google Scholar]
  53. Sekkarie M. A. Torsades de pointes in two chronic renal failure patients treated with cisapride and clarithromycin. Am J Kidney Dis. 1997 Sep;30(3):437–439. doi: 10.1016/s0272-6386(97)90291-2. [DOI] [PubMed] [Google Scholar]
  54. Sesti F., Abbott G. W., Wei J., Murray K. T., Saksena S., Schwartz P. J., Priori S. G., Roden D. M., George A. L., Jr, Goldstein S. A. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci U S A. 2000 Sep 12;97(19):10613–10618. doi: 10.1073/pnas.180223197. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Shaffer Douglas, Singer Sarah, Korvick Joyce, Honig Peter. Concomitant risk factors in reports of torsades de pointes associated with macrolide use: review of the United States Food and Drug Administration Adverse Event Reporting System. Clin Infect Dis. 2002 Jun 19;35(2):197–200. doi: 10.1086/340861. [DOI] [PubMed] [Google Scholar]
  56. Sharma N. D., Rosman H. S., Padhi I. D., Tisdale J. E. Torsades de Pointes associated with intravenous haloperidol in critically ill patients. Am J Cardiol. 1998 Jan 15;81(2):238–240. doi: 10.1016/s0002-9149(97)00888-6. [DOI] [PubMed] [Google Scholar]
  57. Shimizu W., Tanaka K., Suenaga K., Wakamoto A. Bradycardia-dependent early afterdepolarizations in a patient with QTU prolongation and torsade de pointes in association with marked bradycardia and hypokalemia. Pacing Clin Electrophysiol. 1991 Jul;14(7):1105–1111. doi: 10.1111/j.1540-8159.1991.tb02841.x. [DOI] [PubMed] [Google Scholar]
  58. Splawski Igor, Timothy Katherine W., Tateyama Michihiro, Clancy Colleen E., Malhotra Alka, Beggs Alan H., Cappuccio Francesco P., Sagnella Giuseppe A., Kass Robert S., Keating Mark T. Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia. Science. 2002 Aug 23;297(5585):1333–1336. doi: 10.1126/science.1073569. [DOI] [PubMed] [Google Scholar]
  59. Suessbrich H., Schönherr R., Heinemann S. H., Attali B., Lang F., Busch A. E. The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes. Br J Pharmacol. 1997 Mar;120(5):968–974. doi: 10.1038/sj.bjp.0700989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Thomas A. R., Chan L. N., Bauman J. L., Olopade C. O. Prolongation of the QT interval related to cisapride-diltiazem interaction. Pharmacotherapy. 1998 Mar-Apr;18(2):381–385. [PubMed] [Google Scholar]
  61. Tong K. L., Lau Y. S., Teo W. S. A case series of drug-induced long QT syndrome and Torsade de Pointes. Singapore Med J. 2001 Dec;42(12):566–570. [PubMed] [Google Scholar]
  62. Tsai W. C., Tsai L. M., Chen J. H. Combined use of astemizole and ketoconazole resulting in torsade de pointes. J Formos Med Assoc. 1997 Feb;96(2):144–146. [PubMed] [Google Scholar]
  63. Vitola J., Vukanovic J., Roden D. M. Cisapride-induced torsades de pointes. J Cardiovasc Electrophysiol. 1998 Oct;9(10):1109–1113. doi: 10.1111/j.1540-8167.1998.tb00888.x. [DOI] [PubMed] [Google Scholar]
  64. Wang Q., Curran M. E., Splawski I., Burn T. C., Millholland J. M., VanRaay T. J., Shen J., Timothy K. W., Vincent G. M., de Jager T. Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nat Genet. 1996 Jan;12(1):17–23. doi: 10.1038/ng0196-17. [DOI] [PubMed] [Google Scholar]
  65. Wang Q., Shen J., Splawski I., Atkinson D., Li Z., Robinson J. L., Moss A. J., Towbin J. A., Keating M. T. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell. 1995 Mar 10;80(5):805–811. doi: 10.1016/0092-8674(95)90359-3. [DOI] [PubMed] [Google Scholar]
  66. Yang Ping, Kanki Hideaki, Drolet Benoit, Yang Tao, Wei Jian, Viswanathan Prakash C., Hohnloser Stefan H., Shimizu Wataru, Schwartz Peter J., Stanton Marshall. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation. 2002 Apr 23;105(16):1943–1948. doi: 10.1161/01.cir.0000014448.19052.4c. [DOI] [PubMed] [Google Scholar]
  67. Yang T., Roden D. M. Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence. Circulation. 1996 Feb 1;93(3):407–411. doi: 10.1161/01.cir.93.3.407. [DOI] [PubMed] [Google Scholar]

Articles from Netherlands Heart Journal are provided here courtesy of Springer

RESOURCES